Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ageing, serotonin and ketanserin.

A Breckenridge1

  • 1Department of Pharmacology and Therapeutics, University of Liverpool, United Kingdom.

Drugs
|January 1, 1988
PubMed
Summary

Ketanserin, an S2-serotonergic receptor antagonist, demonstrates greater antihypertensive efficacy in elderly patients compared to younger individuals. Adverse effects like dizziness were more common in younger patients, suggesting age-related differences in drug response.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regulatory Consequences of "Brexit" for the Development of Medicinal Products.

Clinical pharmacology and therapeutics·2017
Same author

Regulatory review: How do agencies ensure the quality of decision making?

Clinical pharmacology and therapeutics·2013
Same author

Advancing the science of medicines regulation: the role of the 21st-century medicines regulator.

Clinical pharmacology and therapeutics·2012
Same author

The challenges of orphan drugs and orphan diseases: real and imagined.

Clinical pharmacology and therapeutics·2012
Same author

Interactions with warfarin.

British journal of clinical pharmacology·2012
Same author

European perspective on risk management and drug safety.

Clinical pharmacology and therapeutics·2011

Area of Science:

  • Pharmacology
  • Geriatrics
  • Cardiovascular Medicine

Background:

  • Ketanserin is an S2-serotonergic receptor antagonist with known antihypertensive properties.
  • Clinical observations suggest that ketanserin's effectiveness in lowering blood pressure varies with patient age.

Purpose of the Study:

  • To investigate the relationship between patient age and the antihypertensive efficacy of ketanserin.
  • To compare ketanserin's efficacy and adverse effects across different age groups.

Main Methods:

  • Acute intravenous administration of ketanserin (10mg) in 57 patients aged 25-90 years.
  • Long-term comparative studies of ketanserin versus metoprolol and hydrochlorothiazide in patients above and below 60 years.
  • Analysis of data from 15 double-blind studies.

Main Results:

  • A significant negative correlation was observed between age and the reduction in systolic and diastolic blood pressure after acute ketanserin administration.
  • Ketanserin and hydrochlorothiazide showed greater antihypertensive efficacy in elderly patients (>60 years) compared to younger patients.
  • Adverse effects such as dizziness, somnolence, and dry mouth were more frequent in younger patients.

Conclusions:

  • Ketanserin exhibits a differential antihypertensive effect based on patient age, being more pronounced in the elderly.
  • Age-related differences in ketanserin's efficacy and side effect profile are not explained by pharmacokinetics or dose adjustments.
  • Potential mechanisms for the enhanced efficacy in the elderly may involve serotonin's vasoconstrictor properties in atheroma, though further research is needed.

Related Experiment Videos